CLALIT HEALTH SERVICES

Research presented at the European Congress on Obesity suggests weight loss injections may reduce obesity-related cancer risk by nearly 50%, potentially through anti-inflammatory mechanisms beyond simple weight reduction.

IR-MED's PressureSafe device demonstrated 89% sensitivity and 90% specificity in Israeli clinical studies, with no adverse events across 1,475 scans for pressure injury assessment.

Multiple large-scale real-world studies consistently demonstrate that apixaban is associated with 31-45% lower risk of major bleeding events compared to rivaroxaban in patients with non-valvular atrial fibrillation.